An inborn error of metabolism (IEM) is a genetic condition in which the body cannot properly break down or process a specific nutrient from food. Each IEM involves a missing or malfunctioning enzyme, a tiny biological tool that normally converts one substance into another. When that enzyme doesn’t work, the substance it was supposed to process builds up to toxic levels, or the product it was supposed to create never gets made. Either way, the body’s chemistry goes wrong. Collectively, IEMs affect roughly 1 in every 4,300 newborns in the United States, with similar rates reported worldwide.
How These Disorders Work
Your body runs on thousands of chemical reactions that convert food into energy, building materials, and waste products ready for disposal. Each reaction depends on a specific enzyme. In an IEM, a gene mutation means one of those enzymes is either absent or doesn’t function correctly. The consequences fall into a few patterns.
When the enzyme’s job is to break something down, the unprocessed substance accumulates. Think of it like a blocked drain: the material backs up and eventually causes damage. In some conditions, the buildup is a specific amino acid from protein. In others, it’s ammonia, a normal byproduct the body usually converts into something harmless and excretes. When ammonia accumulates instead, it becomes toxic, particularly to the brain.
When the enzyme’s job is to produce something essential, the body ends up deficient. For example, if a pathway that releases stored sugar is broken, the result is dangerously low blood sugar. If a pathway that burns fat for energy fails, the body loses access to a major fuel source and acids build up in the blood.
Genetics and Inheritance
Nearly all IEMs follow an autosomal recessive inheritance pattern. That means a child must inherit a defective copy of the same gene from both parents to develop the condition. Each parent carries one working copy and one broken copy, so they never show symptoms themselves. When two carriers have a child together, there is a 25% chance per pregnancy that the child will inherit both broken copies and be affected.
A smaller number of IEMs are linked to the X chromosome. Because males have only one X chromosome, a single defective gene is enough to cause disease. Females, with two X chromosomes, can often compensate with their second copy and remain symptom-free carriers. Ornithine transcarbamylase deficiency, a disorder that impairs the body’s ability to process ammonia, is the most common example of this X-linked pattern.
Signs That Something Is Wrong
Many IEMs first appear in the newborn period, sometimes within days of birth. The most frequent early signs are feeding refusal (seen in about 70% of hospitalized newborns later diagnosed with an IEM), low muscle tone (60%), and seizures (40%). Parents often notice a baby who seemed healthy at birth becoming increasingly lethargic, limp, or uninterested in feeding. Vomiting that doesn’t respond to typical remedies is another red flag.
These symptoms reflect what’s happening in the brain. In 85% of cases, the dominant problem is encephalopathy, a broad term for brain dysfunction caused by the accumulation of a toxic substance (like ammonia or certain acid byproducts) or a shortage of something the brain needs (like glucose). Without treatment, this can progress to coma and permanent brain injury.
Not all IEMs present dramatically in infancy, though. Some cause subtler problems that emerge over months or years: developmental delays, difficulty gaining weight, unusual body odors, or episodes of illness triggered by fasting or common infections. A few IEMs don’t show symptoms until adulthood.
How Newborn Screening Catches Them Early
In the United States, every newborn receives a heel-prick blood test in the first day or two of life. This test screens for a panel of conditions recommended by the Department of Health and Human Services, known as the Recommended Uniform Screening Panel (RUSP). The metabolic conditions on this panel fall into three broad groups.
- Amino acid disorders: conditions where the body can’t process specific building blocks of protein. These include phenylketonuria (PKU), maple syrup urine disease, homocystinuria, and tyrosinemia type I.
- Organic acid disorders: conditions involving the incomplete breakdown of proteins or fats, leading to acid buildup. Examples include propionic acidemia, methylmalonic acidemia, and glutaric acidemia type I.
- Fatty acid oxidation disorders: conditions where the body can’t efficiently convert stored fat into energy, particularly dangerous during fasting or illness. Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is the most common.
The panel also includes a few storage disorders like Pompe disease and mucopolysaccharidosis types I and II, where the body can’t break down complex sugars inside cells. As of July 2024, the RUSP lists over 35 core conditions, many of them metabolic. Early detection through screening is what makes the difference between a child who develops normally and one who suffers preventable brain damage or organ failure.
The Main Categories of IEMs
Doctors generally organize the hundreds of known IEMs into a few functional groups based on what goes wrong.
Small molecule disorders involve the pathways that break down nutrients: amino acids from protein, sugars from carbohydrates, and fatty acids from fat. These are the disorders most commonly caught by newborn screening because their chemical signatures show up clearly in a blood sample. They tend to cause acute crises, sometimes called “intoxication” disorders, because a toxic substance accumulates quickly.
Energy metabolism disorders affect the cell’s ability to generate energy, particularly in the mitochondria. Because energy production is critical to every organ, these conditions often cause problems in multiple body systems at once, especially those with high energy demands like the brain, heart, and muscles.
Complex molecule disorders involve the buildup or faulty production of large, complex molecules inside cells. Lysosomal storage disorders like Gaucher disease, Fabry disease, and Pompe disease fall into this category. In these conditions, cellular “recycling centers” called lysosomes can’t break down certain materials, which gradually accumulate and damage organs over time.
Treatment Through Diet
For many IEMs, the cornerstone of treatment is controlling what goes into the body. If the problem is an inability to process a specific amino acid, the solution is to dramatically restrict that amino acid in the diet while still providing enough total nutrition for growth.
PKU is the clearest example. People with PKU can’t properly break down phenylalanine, an amino acid found in virtually all protein-containing foods. Treatment involves limiting natural protein to small, carefully measured amounts and replacing the rest with a medical formula that contains all essential amino acids except phenylalanine. In practice, a child with PKU might get only about 4 grams of natural protein per day from regular food, with a special formula providing another 42 grams of protein and the majority of their daily calories. Total protein needs for someone with PKU run about 30% higher than normal recommendations because the body uses these modified protein sources less efficiently.
Similar strategies apply to maple syrup urine disease, organic acidemias, and urea cycle disorders, each with its own restricted amino acid or nutrient. Specialized low-protein versions of everyday foods like bread, pasta, and cereal help make these diets livable. For some conditions, high-dose vitamins that act as helpers for the defective enzyme can partially restore its function, reducing the severity of dietary restrictions.
Enzyme Replacement and Other Therapies
For IEMs where the missing enzyme can be manufactured and delivered into the body, enzyme replacement therapy offers a more direct fix. This approach has the strongest evidence in lysosomal storage disorders. Patients receive regular infusions of the enzyme their body can’t make. Approved enzyme replacement therapies exist for Gaucher disease, Fabry disease, Pompe disease, Hunter syndrome, and several types of mucopolysaccharidosis.
These treatments don’t cure the underlying genetic defect, but they can slow or prevent organ damage when started early. For Pompe disease, which weakens the heart and muscles, enzyme replacement can be lifesaving when begun in infancy. For Fabry disease, which causes progressive kidney, heart, and nerve damage, early treatment helps preserve organ function over decades.
Organ transplantation, particularly liver transplant, is sometimes used for severe IEMs where the liver is the primary site of the missing enzyme. Gene therapy, which aims to correct the defective gene itself, is an active area of development for several conditions.
What Happens Without Treatment
The consequences of missed or delayed diagnosis can be severe. Because so many IEMs affect the brain, the most common long-term damage is neurological: intellectual disability, seizure disorders, movement problems, and developmental delays. PKU is a striking example. Before newborn screening existed, untreated PKU was one of the leading causes of intellectual disability. With early detection and dietary treatment, children with PKU develop normally.
Beyond the brain, untreated IEMs can cause liver failure, heart damage, kidney disease, and bone abnormalities depending on which pathway is affected. Some conditions are fatal in infancy without intervention. Others cause a slow, progressive decline over years. The window for preventing damage is often narrow, which is why newborn screening programs exist and why the first days of life matter so much for these conditions.